The FKSG80 Inhibitors represent a notable class of chemical entities that have garnered substantial attention within the scientific community due to their distinct mechanisms of action and their implications in various biological contexts. Structurally, these inhibitors possess a carefully crafted molecular framework that encompasses a range of functional moieties. These moieties collectively confer the inhibitors with the capacity to intricately interact with the FKSG80 protein, a vital player in numerous intricate biochemical pathways. Central to the FKSG80 Inhibitors' functionality is their ability to selectively bind to the active site of the FKSG80 protein. This interaction is mediated through a network of non-covalent bonds, including hydrogen bonding, electrostatic interactions, and van der Waals forces. As a consequence of this binding, the normal biochemical activities of the FKSG80 protein are perturbed, resulting in a series of downstream effects that reverberate throughout various cellular processes fundamentally regulated by the FKSG80 protein's function.
The FKSG80 Inhibitors have become indispensable tools in elucidating the intricacies of the FKSG80 protein's biological roles. By selectively inhibiting its activity, researchers can observe and analyze the resulting cellular responses, thereby uncovering novel insights into the protein's involvement in diverse physiological and pathological pathways. This class of inhibitors has found utility in various research disciplines, ranging from basic molecular biology to more specialized fields like signal transduction studies and cellular pathway elucidation. Ongoing investigations continue to unravel the precise molecular interactions between the FKSG80 Inhibitors and their target protein, shedding light on the nuances of their binding kinetics and thermodynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Binds to the ATP-binding site of Bcr-Abl tyrosine kinase, inhibiting its activity and interfering with downstream signaling pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), inhibiting its autophosphorylation and downstream signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, including RAF kinases and VEGFR-2, reducing angiogenesis and tumor cell proliferation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Blocks the activity of multiple tyrosine kinases, including Bcr-Abl and Src-family kinases, disrupting their signaling pathways. Approved for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). | ||||||